Insulin glargine biosimilar - Boehringer Ingelheim/Eli Lilly

Drug Profile

Insulin glargine biosimilar - Boehringer Ingelheim/Eli Lilly

Alternative Names: Abasaglar; Abasria; Basalgar; LY-2963016; LY2963016 U-100; LY2963016 U-200

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 17 Nov 2017 Eli Lilly plans a phase III trial for Type-1 diabetes mellitus (Combination therapy) in China in March 2018 (NCT03338023)
  • 17 Nov 2017 Eli Lilly plans a phase III trial for Type-2 diabetes mellitus (Adjunctive treatment) in China in February 2018 (NCT03338010)
  • 09 Jun 2017 Efficacy and adverse events data from the phase III ELEMENT-5 trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top